General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Expected to Earn FY2024 Earnings of ($4.50) Per Share | news.google.com • |
Intellia (NTLA) Up on Positive Data Updates From HAE Study | news.google.com • |
Does Intellia Therapeutics (NASDAQ:NTLA) Have A Healthy Balance Sheet? | news.google.com • |
6747 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Acquired by Vanguard Personalized Indexing Management ... | news.google.com • |
3 Of My Favorite Names On Wells Fargo's Biotech Buyout List | seekingalpha.com • |
Intellia Therapeutics (NASDAQ:NTLA) Trading Down 3.6% | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-09 | 2024-03 | -1.35 | -1.06 | 0.29 | 21.48% |
2024-02-22 | 2023-12 | -1.47 | -1.46 | 0.01 | 0.68% |
2023-11-09 | 2023-09 | -1.52 | -1.38 | 0.14 | 9.21% |
2023-08-03 | 2023-06 | -1.32 | -1.4 | -0.08 | -6.06% |
2023-05-04 | 2023-03 | -1.41 | -1.17 | 0.24 | 17.02% |
2023-02-23 | 2022-12 | -1.4 | -1.4 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-12 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-28 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-08 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-06 | Chardan Capital | Upgrade | Buy | Buy |
2023-08-06 | Canaccord Genuity | Upgrade | Buy | Buy |
2023-08-06 | Barclays | Upgrade | Overweight | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-03 | BASTA JAMES EDMUND | General Counsel | 81.57K | Sale |
2023-10-30 | BHANJI MUNA | Director | 12.00K | Sale |
2024-03-03 | CLARK ELIANA | Chief Technology Officer | 71.47K | Sale |
2023-06-13 | COHEN FREDERICK E. M.D. PH.D. | Director | 41.72K | Stock Award(Grant) |
2023-06-13 | CROWLEY JOHN FRANCIS | Director | 11.72K | Stock Award(Grant) |
2024-02-29 | GODDARD GLENN G | Chief Financial Officer | 69.21K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | ARK Investment Management, LLC | 9.95M | 314.58M | 11.24% |
2023-06-29 | Vanguard Group Inc | 8.19M | 333.79M | 9.25% |
2023-06-29 | Blackrock Inc. | 8.05M | 328.48M | 9.10% |
2023-06-29 | State Street Corporation | 3.49M | 142.44M | 3.95% |
2023-06-29 | Nikko Asset Management Americas, Inc. | 3.39M | 138.43M | 3.84% |
2023-06-29 | Sumitomo Mitsui Trust Holdings, Inc. | 3.39M | 138.43M | 3.84% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | ARK ETF Tr-ARK Innovation ETF | 6.78M | 214.49M | 7.67% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 2.62M | 107.02M | 2.97% |
2023-06-29 | Vanguard Small-Cap Index Fund | 2.16M | 88.16M | 2.44% |
2023-09-29 | ARK ETF Tr-ARK Genomic Revolution ETF | 2.03M | 64.22M | 2.30% |
2023-08-30 | iShares Russell 2000 ETF | 2.01M | 75.44M | 2.27% |
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.62M | 60.77M | 1.83% |
Some winning perspectives $NTLA from last 4 months. March high 80. April high upper 80’s. May high was $78. June again 80+ and then hit $202! So now even if offering goes as low as 125, which it is not. Offering btw 140-160. No way, $NTLA will go below 80 or 100 or 125! It’s only going to trend higher & higher After successful phase 1 study and another phase 2 study just around the corner. Plus $NTLA has partnership with Novartis
Only AHoles bears doubt create FUD about pharma and phase studies …Bc they want to kill companies by attacking their potential. You all think companies investing millions to ruin themselves w failed studies???
These aHoles don’t know…that those who bought it above $180 or so, are not paper hands or folks w odd jobs or replying on stipend from govt! Serious buyers w long term plans …and it’s not just an average person but big firms that bought and are holding
Don’t be scared it’s only going down Bc Nasdaq is being manipulated! By wall street sec …they can’t keep it down forever …buy at dips & hold ur hands
It’s not a bull trap, normal trading day fluctuations! Nasdaq clears a little more green & it will keep shooting above 200
Go to social media other boards and tell ur friends to join & invest in $NTLA , maybe possible squeeze as bears have to cover soon.
Don’t listen to bears, FUD, or any big bank valuation! It’s your own DD. Hold long & strong bc $NTLA has billions & unique product to offer into market which is gene manipulation! You can’t phantom it’s scope in healthcare
Have faith my fellow apes! $NTLA about to rip thru holes. Told you all…hold ur ground
Everyone set high sell limits & remove all stop loss …this will rip above $250 today
Vol is going inc automatically Bc stock is hot it’s biotech and unique w gene manipulation to cure disease …those who know the value will invest even at $250
Stay strong ….buy buy buy
Get some good Nite sleep you all who had a tough day. Tomorrow have fun & watch bears chase this stock $NTLA to $250!
Futures are green! Bears dead tomorrow. Will have to cover in pre-market Their shorts will burn right into the open Buy Buy now at this low price before it hits $250 tomorrow
Guys i just compared 5 year avg growth rates of $NTLA PROFILE w renowned $NVS pharma on WSJ. Would you know, $NTLA revenue & net incomes are 50% more that of Novartis! Earnings per share almost 10% up! Though NVS has $207B in market cap. You have a diamond hand. Hold and prosper soon! Don’t let this price offering action distract you. And pls go to WSJ and see for urself
@Ross I looked into EDIT today & it was not for me. Was moving too slow. Maybe when Nasdaq is strong it might excel then
Question, can someone answer: once a secondary price offering accepted by institutional investors, is there a lock in period that they can’t sell shares? Like after an ipo offering there is a wait of 180 days for employees.
And oh! Fuck JPM and any others w lower price targets! Trust $NTLA Bc company is strong, has capital, & partnerships w huge pharma like Novartis. Plus gene therapy is a powerful game changer! Trust this company for very near success & future ahead!